Fig. 2
From: Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma
Changes in survivin expression, proliferation and apoptosis in tumor tissue from dogs with lymphoma treated with EZN-3042.a Survivin expression in tumor tissues before and after EZN-3042 treatment as assessed by immunohistochemistry. b Tumor cell proliferation assessed immunohistochemically via Ki-67 labeling index in tumor tissues before and after EZN-3042 treatment. c Tumor cell apoptosis assessed via activated caspase-3 immunohistochemistry in tumor tissues before and after EZN-3042 treatment. In all figures, black arrows indicate samples where reduction in tumor survivin mRNA expression was observed